IP Library Granted Patent US 9,499,593
Granted Patent B2
US 9,499,593 · App. 14/116,492 · Granted Nov 22, 2016

Modified biotin-binding protein, fusion proteins thereof and applications

Inventors: Richard Malley (Beverly, MA); Yingjie Lu (West Roxbury, MA); Fan Zhang (West Roxbury, MA)
Assignee: Children's Medical Center Corporation
C07K14/31A61K47/48046A61K2039/6031C07K2319/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,593
App. No.
14/116,492
Granted
Nov 22, 2016
Kind
B2
Abstract

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

Claims (9)

1. A vaccine composition comprising a soluble biotin-binding protein consisting essentially of an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1, wherein the biotin-binding protein has a higher solubility than the biotin-binding protein of SEQ ID NO: 4.

2. The vaccine composition of claim 1 , wherein the soluble biotin-binding protein further comprises one or more of: a signal sequence, a lipidation sequence, a purification tag, a linker peptide, and a spacer peptide.

3. An immunogenic composition comprising at least one soluble biotin-binding protein, wherein the soluble biotin-binding protein consists essentially of an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1, wherein the biotin-binding protein has a higher solubility than the biotin binding protein of SEQ ID NO: 4, and wherein the soluble biotin-binding protein optionally further comprises one or more of: a signal sequence, a lipidation sequence, a purification tag, a linker peptide, and a spacer peptide.

4. The immunogenic composition of claim 3 , further comprising at least one or more of: a polysaccharide, and a polypeptide.

5. The immunogenic composition of claim 4 , comprising at least one polysaccharide and at least one polypeptide.

6. The immunogenic composition of claim 5 , wherein the at least one polysaccharide is associated with a first affinity molecule.

7. The immunogenic composition of claim 5 , wherein the soluble biotin-binding protein is non-covalently associated with the at least one polypeptide.

8. The immunogenic composition of claim 5 , wherein the at least one polysaccharide is associated with a first affinity molecule, and the soluble biotin-binding protein is non-covalently associated with the at least one polypeptide.

9. The immunogenic composition of claim 8 , wherein the first affinity molecule associates with the soluble biotin-binding protein to link the polypeptide and the polysaccharide.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 15, 2017
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042459/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2013
From: MALLEY, RICHARD; LU, YINGJIE; ZHANG, FAN
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 031639/0836 →
Continuity (4)
Provisional Application 61484934 · May 11, 2011
Provisional Application 61608168 · Mar 8, 2012
Provisional Application 61609974 · Mar 13, 2012
Related Publication 20140154286A1 · Jun 5, 2014